Free Trial
NASDAQ:MBRX

Moleculin Biotech (MBRX) Stock Price, News & Analysis

Moleculin Biotech logo
$0.57 -0.03 (-4.88%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$0.57 0.00 (-0.11%)
As of 08/22/2025 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Moleculin Biotech Stock (NASDAQ:MBRX)

Key Stats

Today's Range
$0.56
$0.60
50-Day Range
$0.27
$0.84
52-Week Range
$0.25
$3.65
Volume
1.94 million shs
Average Volume
2.55 million shs
Market Capitalization
$17.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Moleculin Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

MBRX MarketRank™: 

Moleculin Biotech scored higher than 59% of companies evaluated by MarketBeat, and ranked 464th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Moleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Moleculin Biotech has only been the subject of 1 research reports in the past 90 days.

  • Read more about Moleculin Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Moleculin Biotech are expected to grow in the coming year, from ($7.98) to ($4.79) per share.

  • Percentage of Shares Shorted

    14.73% of the float of Moleculin Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Moleculin Biotech has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Moleculin Biotech has recently decreased by 22.37%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Moleculin Biotech does not currently pay a dividend.

  • Dividend Growth

    Moleculin Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.73% of the float of Moleculin Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Moleculin Biotech has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Moleculin Biotech has recently decreased by 22.37%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Moleculin Biotech has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Moleculin Biotech this week, compared to 2 articles on an average week.
  • Search Interest

    Only 10 people have searched for MBRX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Moleculin Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $350,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 2.10% of the stock of Moleculin Biotech is held by insiders.

  • Percentage Held by Institutions

    Only 15.52% of the stock of Moleculin Biotech is held by institutions.

  • Read more about Moleculin Biotech's insider trading history.
Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Stock News Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
HC Wainwright Analysts Raise Earnings Estimates for MBRX
See More Headlines

MBRX Stock Analysis - Frequently Asked Questions

Moleculin Biotech's stock was trading at $1.70 at the start of the year. Since then, MBRX shares have decreased by 66.6% and is now trading at $0.5676.

Moleculin Biotech, Inc. (NASDAQ:MBRX) issued its earnings results on Tuesday, August, 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.10.

Moleculin Biotech shares reverse split on Friday, March 22nd 2024.The 1-15 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Moleculin Biotech investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
8/12/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MBRX
CIK
1659617
Fax
N/A
Employees
20
Year Founded
2006

Price Target and Rating

High Price Target
$4.00
Low Price Target
$4.00
Potential Upside/Downside
+604.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.76 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,498.41%
Return on Assets
-114.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.15
Quick Ratio
1.15

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.24) per share
Price / Book
-2.37

Miscellaneous

Outstanding Shares
30,286,000
Free Float
29,650,000
Market Cap
$17.19 million
Optionable
Not Optionable
Beta
1.39

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:MBRX) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners